Acer Therapeutics — Investor Presentation (January 2019)
35 slides from Acer Therapeutics's investor presentation, Jan 7, 2019
Slide 1: Corporate Presentation January 2019
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Critical Unmet Medical Needs Corporate Presentation January 2019 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with critical unmet medical needs Headquartered: Newton, MA Headcount: 24 Founded: December 2013 Public: September 2017 Cash: $46.2M as of S
Slide 4: Executive Leadership Team
Executive Leadership Team Chris Schelling CEO & Founder 20 years; strategic commercial development & orphan Will Andrews, MD Chief Medical Officer 19 years; clinical development, medical affairs & orphan M.D. Yale University School of Medicine Salma Jutt, MBA Chief Commercial Officer 20 years; sales
Slide 5: Investment Highlights
Investment Highlights Acer's pipeline includes three clinical-stage candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a fully taste-masked, immediate release formulation of sodium ph
Slide 6: Clinical Pipeline
Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 2 Phase 3 Phase 3 NDA NDA Market Market EDSIVOTM (celiprolol) vEDS (COL3A1+) Improves hemodynamic stability; decreases vascular resistance ACER-001 (reformulated sodium phenylbutyrate) UCD Comparable to Buphenyl; taste-mas
Slide 7: EDSIVO has a unique pharmacological profile
EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO™ positive effects in vEDS thought to be through vasodilation, providing more stable hemodynamic conditions
Slide 8: EDSIVO Unique Mechanism of Action
Cardiology in Review 2017;25: 247–253. * Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: Selective β1 and ⍺2 adrenergic receptor antagonist β2 and β3 adrenergic receptor agonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates
Slide 9: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Gastrointestinal Uterine Autosomal dominant (50%); spontaneous mutations (50%) Diagnosed by clinical symptom
Slide 10: EDSIVO Pivotal Clinical Trial
Statistically-significant Efficacy: Trial stopped early for treatment benefit (mean follow-up 47 months) The primary endpoint (arterial dissection or rupture) affected 5 (20%) celiprolol patients and 14 (50%) controls (hazard ratio [HR] 0.36; p=0.04) Primary and secondary endpoints (intestinal or ut
Slide 11: EDSIVO vEDS Registry
Assistance Publique – Hôpitaux de Paris (AP-HP) Registry PIs: Michael Frank, Xavier Jeunemaitre 144 patients enrolled in registry 100% of patients in registry have COL3A1 gene mutation >80% of patients treated with celiprolol Study Period: Jan. 2000 to Dec. ‘14 (for initial referral patients), follo
Slide 12: EDSIVO Launch Plan
EDSIVO™ Launch Plan* * Commercialization of EDSIVO is subject to FDA approval Market Access Ecosystem Goals: To ensure optimal pricing and access to all COL3A1+ patients Robust HCP & Patient Support Programs Key Activities: Establish “Acer Care” Patient Support Services Payer Engagement Plan HCP / P
Slide 13: EDSIVO vEDS Market Sizing
Acer survey of commercial genetic labs for confirmed COL3A1+ vEDS = ~2,000 patients HVH Evaluation (Truven Health MarketScan* = 190M covered lives)* vEDS patient population for basis of market sizing = 4,169 patients This projects the potential vEDS patients (U.S. population (2018) = 325M) = ~7,100
Slide 14: EDSIVO Genetic Testing Program (COL3A1)
EDSIVO™ Genetic Testing Program (COL3A1) Goal: Provide DNA sequencing via NGS or Sanger sequencing (the test should be predicted to detect disease mutation in at least 95% of individuals with vEDS) Confirm COL3A1+ status of clinically diagnosed patients Identify and test family members Details integ
Slide 15: EDSIVO Patient Advocacy
EDSIVO™ Patient Advocacy Find and engage vEDS patients Support community growth vEDS educational programs Genetic testing awareness Relationship for legislative support Development of national vEDS organization
Slide 16: vEDS Network of Excellence
vEDS Reference Centers Identify vascular medicine specialists / cardiologists who: Can manage patients and their families Refer to CV surgeons Work closely with a team of specialists Expand specialist support team Care for other aspects of disease management Includes: GI, OB/GYN, Genetics, Surgeons,
Slide 17: EDSIVO vEDS KOL Advisory Board
EDSIVO™ vEDS KOL Advisory Board 8 Top vEDS Centers in U.S. Held: November 12, 2018 in NYC Agreement amongst attendees on positive benefit-risk profile of celiprolol in vEDS Celiprolol real world therapeutic effects on: Survival improvement & dose response effects Hospitalizations Disease progression
Slide 18: EDSIVO Market Access Ecosystem
EDSIVO™ Market Access Ecosystem Securing Patient Access requires strategic alignment of Market Access Ecosystem Acer Care Patient Support Services Genetic Testing Payer Engagement Plan Innovative pricing model Patient & HCP / KOL Advocacy EDSIVO Value Proposition HUB / SPP Operational Excellence Ded
Slide 19: EDSIVO Health Economic Outcome Research
Precision Health Economics is developing a health economic (cost-consequence) model demonstrating the economic and clinical value of vEDS Centers of Excellence, and the potential impact of EDSIVO™ on patient outcomes These models will help quantify and communicate cost offsets associated with the CO
Slide 20: EDSIVO Market Opportunity
If approved, EDSIVO™ will be the only FDA-approved therapy to treat vEDS patients Up to 5,000 COL3A1+ vEDS patients in the U.S. 50-100 Centers of Excellence Focused, dedicated field support (n~20-25 people) Orphan pricing well supported by initial payer research, with additional validation from phar
Slide 21: ACER-001 taste-masked sodium phenylbutyrate
Small molecule with unique MOAs in various disorders UCD: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCD: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCD: Currently treated with Ravicti, Buphenyl, Ammonul, a
Slide 22: ACER-001 Urea Cycle Disorders (UCDs)
Urea cycle disorders are a group of genetic disorders caused by mutations that result in a deficiency of one of the six enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the blood stream The estimated incidence of urea cycle disorders is 1 in 35,000 births1 Treatment
Slide 23: ACER-001 Maple Syrup Urine Disease
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 24: Lower BCAAs in UCD & MSUD
In addition to lowering levels of ammonia in patients with urea cycle disorders (UCD), sodium phenylbutyrate (NaPB) also significantly reduces branched-chain amino acids (BCAAs)1 NaPB’s ability to lower leucine and other BCAAs could provide clinically-meaningful benefit in another genetic disease: M
Slide 25: ACER-001 Taste-Masked, Immediate Release Formulation
Acer is working closely with KOLs & patient advocacy groups to provide a compelling alternative treatment option for patients with UCD ACER-001 provides significant differentiation from other approved formulations of phenylbutyrate Ravicti / Buphenyl reported 2017 revenue $214.7M (U.S. / UCD only)*
Slide 26: ACER-001 Market Opportunity
Cannibalize existing sodium phenylbutyrate market share in UCD 2017 U.S. Revenue for Ravicti & Buphenyl = $214.7M (n~600 patients) Well differentiated formulation Will be competitively priced Life cycle expansion opportunity in MSUD Barriers to entry: Filed formulation patent application (January 20
Slide 27: Osanetant NK3 receptor antagonist
Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus NKB/NK3R is implicated in a variety of human functions and affects the hypothalamus-pituita
Slide 28: Osanetant NK3 Receptor (Neurokinin B)
Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d
Slide 29: Role of NKB/NK3R in Neuroendocrinology
Neurokinin B (NKB), a member of the tachykinin-peptide family, has emerged as an important modulator of reproductive function This appears to be mediated, at least partially, by its ability to auto-regulate the activity of Kiss1 neurons in the ARC The NKB system may play a more prominent stimulatory
Slide 30: Mechanism of Vasomotor Symptoms (VMS)
Vasomotor symptoms, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) Osanetant Mechanism of Vasomotor Symptoms (VMS) The Oncologist, Oct 2003, vol.8 no.5 474-487. http://www.everydayhealth.com
Slide 31: NK3R Antagonist Clinical POC in VMS
Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist, originally developed by Ogeda SA Ogeda was acquired by Astellas in 2017 for up to €800M Average Daily Hot Flash Frequency Reported as per FDA Guidance * : % decrease from the baseline At
Slide 32: NK3R Antagonist Clinical POC in VMS
Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist, originally developed by Ogeda SA Ogeda was acquired by Astellas in 2017 for up to €800M Score of average severity of Hot Flash, irrespective of frequency of Hot Flash * : % decrease from
Slide 33: Osanetant Market Opportunity
Acer acquired worldwide rights to osanetant from Sanofi Clinical proof of concept studies with other NK3R antagonists have demonstrated rapid and clinically-meaningful improvement in vasomotor symptoms and PCOS Ogeda SA was acquired by Astellas in 2017 for up to €800M Osanetant was shown to be safe
Slide 34: Financial Overview
Cash: $46.2M as of September 30, 2018 Expected to have sufficient capital into H1 2020 Capitalization as of December 31, 2018: 10.1M shares of common stock outstanding 10.9M shares of common stock fully diluted $87M invested through August 2018 Top investors include: TVM Capital, Nantahala Capital,
Slide 35: Acer's pipeline of three clinical-stage candidates
ACER Acer's pipeline includes three clinical-stage candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for
Acer Therapeutics — Investor Presentation (January 2019) on 6ix